ADBIOTECH Delays Receipt of Balance Payment for Self-Convertible Bond Sale to September 3, 2026; Dilution Risk Remains Unchanged
ADBIOTECH filed a correction to its major report on the sale of self-convertible bonds, delaying the receipt of the balance payment from July 3, 2026 to September 3, 2026. This is the second postponement following a prior delay on May 12, 2026.
The convertible bonds have a conversion price of 1,797 KRW, with 1,669,449 shares to be issued upon conversion, representing 7.82% of total outstanding shares. The total sale price is 3.3 billion KRW, with a deposit of 165 million KRW already received and the balance of 3.135 billion KRW to be received on September 3.
While the delay in the balance payment temporarily postpones cash inflow, the terms of the sale and the purpose of improving financial structure remain unchanged. Existing shareholders still face a potential dilution risk of 7.82%.
[AI Summary]ADBIOTECH has twice delayed the balance payment date for its self-convertible bond sale, postponing the funding timeline but leaving the conversion terms and dilution ratio intact. The 3.3 billion KRW sale is intended for working capital, but the repeated delays may indicate liquidity management challenges.
KOSDAQ Filing Information
[Correction of Description] Report on Major Matters (Decision on Sale of Self-Convertible Bonds)